Scotiabank analyst Jason Mollin downgrades Banco Santander Mexico (NYSE:BSMX) from Sector Outperform to Sector Underperform.
SELLAS Announces Topline Data From GFH009 Phase 1 Dose-Escalation Trial In Acute Myeloid Leukemia Cohort Supporting Advancement To Phase 2 Clinical Study
- 72 Acute Myeloid Leukemia and Lymphoma High-Risk Advanced Patients Enrolled: 94% Alive at Last Assessment Indicating Favorable Survival Benefit -
- Long-Term Complete Remission and Significant Bone Marrow
